14-3-3 Protein in the CSF as prognostic marker in early multiple sclerosis

Neurology

Volumn 57, Issue 4, 2001, Pages 722-724

  Martinez Yelamos A ^a   Saiz, Albert ^b   Sanchez Valle, R ^b   Casado, V ^a   Ramon J M ^a   Graus, F ^b   Arbizu, T ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN PROTEIN; PROTEIN 14 3 3; PROTEIN S 100;

ADULT; ARTICLE; AXONAL INJURY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; DISABILITY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION;

EID: 0035964409     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.57.4.722     Document Type: Article

References (10)

1. Optic neuritis: Prognosis for multiple sclerosis from MRI, CSF, and HLA findings
2. Axonal transection in the lesion of multiple sclerosis
3. Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders
4. The 14-3-3 protein detectable in cerebrospinal fluid of patients with prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture
5. 14-3-3 Protein in cerebrospinal fluid of patients with acute transverse myelitis
6. Are there any body fluid markers of brain atrophy in multiple sclerosis?
7. Short-term prognosis in early relapsing-remitting multiple sclerosis
8. Detection of ventricular enlargement in patients at the earliest clinical stage of MS
9. Intramuscular interferon beta-1 a therapy initiated during a first demyelinating event in multiple sclerosis
10. Interferon beta-1 a (Rebif) in patients with acute neurological syndromes suggestive of multiple sclerosis: A multi-center, randomized, double-blind, placebo-controlled study